Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Bio-heart Biological Technology Co., Ltd. announces that its subsidiary, AngioCare, has reached an agreement with Terumo to waive exclusive distribution rights for its RDN products in the Greater China region, opening opportunities for new collaborations and expanded market reach. This strategic decision aims to leverage internal resources and enhance future commercialization efforts without adversely affecting the company’s operations.
For further insights into HK:2185 stock, check out TipRanks’ Stock Analysis page.